<DOC>
	<DOC>NCT02969109</DOC>
	<brief_summary>A study to validate, in a prospective manner, the ability of the predefined Genomic Health bladder cancer assay to detect recurrence in patients undergoing surveillance for non-muscle invasive bladder cancer.</brief_summary>
	<brief_title>Validation of a Urine-based Assay With Genomic Markers for Predicting Recurrence for Non-muscle Invasive Bladder Cancer</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<criteria>Patients with a prior diagnosis of nonmuscle invasive, â‰¤T1, urothelial cell carcinoma of the bladder scheduled to undergo surveillance cystoscopy. Patients younger than 18 years Patients with a diagnosis of small cell carcinoma, adenocarcinoma or squamous cell carcinoma of the bladder Patients who have had a cystectomy or prior diagnosis of muscle invasive disease (T2 or greater) Patients who are unable or unwilling to give informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>